

AMENDMENTS TO THE CLAIMS:

Amend the claims as follows:

Claims 1-34. (Canceled)

35. (Currently Amended) A mouse ~~having a mutated~~ whose genome comprises a mutant LAT gene, or one allele for a mutant mouse LAT gene. encoding a mutant mouse LAT protein, wherein the sequence of said mutant mouse LAT protein comprises ~~differs from a mouse wild type sequence by~~ a single mutation of a tyrosine located at position 136 of the wild-type mouse LAT protein sequence, ~~[[which]]~~ wherein the mutation is not a composite mutation of the tyrosine residue at positions 175, 195, and 235 of said wild-type mouse LAT protein sequence, ~~[[said]]~~ wherein the single mutation of the tyrosine located at position 136 ~~being replaced by~~ consists of a replacement with a residue preventing the association with the SH2 domain of proteins, ~~[[said]]~~ wherein the mouse ~~[[being]]~~ is homozygous for ~~the mutated~~ said mutant mouse LAT gene or ~~[[being]]~~ is a carrier of a null allele of the LAT gene, and ~~said mutant LAT protein leading to an~~ wherein the mouse has a phenotype of exaggerated TH2 cell differentiation.

Claim 36. (Canceled)

37. (Currently Amended) The mouse according to claim 35, wherein said mutated LAT gene encodes ~~coding for~~ a mutant LAT protein ~~[[comprises]]~~ comprising the mutated amino acid sequence of exon 7 of the mutated gene (SEQ ID NO: ~~[[2]]~~ 3).

38. (Withdrawn – Currently Amended) The mouse ~~non-human animal~~ according to claim 35, wherein the sequence of said mutant mouse LAT protein contains a composite mutation of the three distal tyrosine residues.

Claims 39-42. (Canceled)

43. (Previously Presented) The mouse according to claim 35, wherein said single mutation consists in the replacement of the tyrosine by a phenylalanine (Y-F), an aspartic acid (Y-D) or a glutamic acid (Y-E).

44. (Previously Presented) The mouse according to claim 43, wherein said single mutation consists in the replacement of the tyrosine by a phenylalanine (Y-F).

Claim 45. (Canceled)

46. (Previously Presented) The mouse according to claim 35, wherein said mutated LAT gene is incorporated into the mouse genome by targeted insertion in order to keep said mutated LAT gene under the control of regulatory regions of the endogenous LAT gene.

47. (Previously Presented) A germ cell or somatic cell from the mouse according to claim 35 or any progeny of said mouse containing the mutated LAT gene.

48. (Withdrawn) A method of screening for drugs for treatment of allergy, asthma and/or disease associated with TH2 cell deregulation comprising:

- 1) administering a candidate drug to a rodent according to claim 35;

2) evaluating the effect of said drug on the symptom or sign of allergy, asthma and/or disease associated with TH2 cell deregulation; and

3) selecting the drug that reduces said symptom or sign;

thereby identifying a drug for treatment of allergy, asthma and/or disease associated with TH2 cell deregulation.

49. (Withdrawn) The method according to claim 48, wherein said effect of said drug can be evaluated by measuring at least one parameter selected from the group consisting of IgE level, IgG1 level, interleukin level, and eosinophilia.

50. (Withdrawn) The method according to claim 49, wherein said effect of said drug can be evaluated by measuring the serum level of IgE or IgG1.

51. (Withdrawn) A method of screening drugs for treatment of allergy, asthma and/or disease associated with TH2 cell deregulation comprising:

1) subjecting cells according to claim 47 to a candidate drug;

2) evaluating the effect of said drug on said cells;

3) selecting the drug having the desired effect;

thereby identifying a drug for treatment of allergy, asthma and/or disease associated with TH2 cell deregulation.

52. (Withdrawn) A method of screening for drugs that regulate the activity of TH2 cells, comprising:

- 1) administering a candidate drug to rodent according to claim 35; and
- 2) selecting a drug that modulates the activity of TH2 cells in said non-human animal.

53. (Withdrawn) A method of producing a pharmaceutical composition for treating a disease associated with deregulated TH2 cells activity, the method comprising (i) selecting, identifying, optimizing or characterizing a compound using a screening method according to claim 52 and (ii) conditioning said compound, or a derivative thereof, in a pharmaceutically acceptable carrier or vehicle.

54. (Withdrawn) A method of production of humanized IgE antibodies comprising:

- 1) providing a non-human animal expressing humanized IgE;
- 2) breeding said animal expressing humanized IgE with rodent according to claim 35;
- 3) immunizing the animal of the progeny with an allergen;
- 4) recovering humanized IgE specific to said allergen.

55. (Withdrawn) The method according to claim 54, wherein step 4 comprises producing B cell hybridomas producing said humanized IgE specific to said allergen.

56. (Withdrawn) A B cell hybridoma obtained by the method according to claim 55.

57. (Currently Amended) A ~~mutated-mutant mouse~~ LAT gene encoding ~~eeding~~ for a mutant mouse LAT protein, wherein the sequence of which differs from a wild-type mouse LAT sequence by the mutant mouse LAT protein comprises a single mutation of a tyrosine located at position 136 of the wild-type mouse LAT protein sequence, ~~which~~ wherein the mutation is not a composite mutation of the tyrosine residues at positions 175, 195, and 235 of said wild-type mouse LAT protein sequence, ~~said wherein the~~ single mutation of the tyrosine located at position 136 ~~being replaced by~~ consists of a replacement with a residue preventing the association with the SH2 domain of proteins.

58. (Previously Presented) The mouse gene according to claim 57, wherein said single mutation consists in the replacement of the tyrosine by a phenylalanine (Y-F), an aspartic acid (Y-D) or a glutamic acid (Y-E).

59. (Previously Presented) The mouse gene according to 58, wherein said single mutation consists in the replacement of the tyrosine by a phenylalanine (Y-F).

60. (Previously Presented) The mouse gene according to 57, wherein the mutant sequence is SEQ ID NO:1.

61. (Currently Amended) The mouse gene according to 57, wherein the mutant sequence encodes a mutant LAT protein containing the mutated amino acid sequence of [[contains]]exon 7 of the mutated gene (SEQ ID NO: [[2]]3).

62. (Withdrawn) A diagnostic method for asthma, allergy, eosinophilia and/or TH2 cells deregulation comprising the detection of a mutated LAT gene coding for a mutant LAT protein containing a single mutation of the tyrosine Y136, wherein the detection of said mutated LAT gene is indicative of asthma, allergy, eosinophilia and/or TH2 cells deregulation.

63. (Withdrawn) A diagnostic kit for asthma, allergy, eosinophilia and/or TH2 cells deregulation comprising oligonucleotide probes for the detection of a mutated LAT gene coding for a mutant LAT protein containing a single mutation of the tyrosine Y136, wherein the detection of said mutated LAT gene is indicative of asthma, allergy, eosinophilia and/or TH2 cells deregulation.

64. (Withdrawn) A mouse resulting from the breeding of a mouse expressing humanized IgE with the mouse according to claim 35.